Abstract:Cancer immunotherapy with ICB is considered a promising strategy for cancer treatment. In silico prediction of the ICB response is an important step toward achieving effective and personalized cancer immunotherapy. Three challenging issues remain: (i) Identifying highly predictive biomarkers by deciphering and understanding the interaction between tumor and immune cells; (ii) efficiently obtaining and predicting these biomarkers using HTS data; and (iii) building effective computational models that integrate these biomarkers for improved ICB response prediction. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. immune checkpoints are molecules in the immune system that either enhance or attenuate a signal. Tumors protect themselves from the immune system by inhibiting the T cell signal. The use of inhibitors to block inhibitory checkpoint molecules by recovering the anticancer immune response is referred to as ‘immune checkpoint blockade’. peptides presented by MHC class I or MHC class II molecules on the tumor cell surface. These peptides derive from tumor-specific somatic mutations and are not expressed in normal cells. the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix. The tumor and surrounding microenvironment are closely related and constantly interact. Effective immunotherapy often requires changes to the TME. V-J recombination is the unique mechanism of genetic recombination that occurs in developing lymphocytes during the early stages of T and B cell maturation. It involves somatic recombination in a nearly random fashion, which rearranges variable (V), joining (J), and, in some cases, diversity (D) gene segments. This has resulted in the highly diverse repertoire of antibodies and/or immunoglobulins (Igs) and T cell receptors (TCRs) found on B cells and T cells, respectively.

[Identification of Predictive Biomarkers for Immune Checkpoint Inhibitors by Immunogenomics]

Computational immunogenomic approaches to predict response to cancer immunotherapies

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Towards in Silico Prediction of the Immune-Checkpoint Blockade Response

Identifying the Immunological Gene Signatures of Immune Cell Subtypes

Integrated Genomic Characterization of the Human Immunome in Cancer

The Immune Landscape of Cancer

Technological Advances in Cancer Immunity: from Immunogenomics to Single-Cell Analysis and Artificial Intelligence

Historical perspective and future directions: computational science in immuno-oncology

Current transcriptome database and biomarker discovery for immunotherapy by immune checkpoint blockade

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories

Contemplating immunopeptidomes to better predict them

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

The Immunoscore: Colon Cancer and Beyond

Identification of tumor antigens with immunopeptidomics

Uncovering Predictive Gene and Cellular Signatures for Checkpoint Immunotherapy Response through Machine Learning Analysis of Immune Single-Cell RNA-seq Data

The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides

Identification of Colon Immune Cell Marker Genes Using Machine Learning Methods.

Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis